Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Flora Poizat

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1604-3422; OpenAlex author ID A5001651792. Sources: ClinicalTrials.gov.

Their work

Papers
23
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: none · 2012: none · 2013: 1 paper · 2014: none · 2015: 3 papers · 2016: 3 papers · 2017: 4 papers · 2018: 1 paper · 2019: 1 paper · 2020: 5 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 3 papers

Papers 23

  1. Surgery for Locally Advanced Pancreatic Cancer: Oncological Landmarks for Venous and Arterial Reconstruction. Co-author DOI 10.1245/s10434-025-18768-7↗
  2. ASO Visual Abstract: Surgery for Locally Advanced Pancreatic Cancer: Oncological Landmarks for Venous and Arterial Reconstruction. Co-author DOI 10.1245/s10434-025-19023-9↗
  3. Transcriptomic FOLFIRINOX sensitivity signatures stratify overall survival and reveal directional reclassification after neoadjuvant FOLFIRINOX in borderline r… Co-author DOI 10.64898/2026.09.07.749857↗
  4. A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2022.11.035↗
  5. Prospective Evaluation of Resection Margins Using Standardized Specimen Protocol Analysis among Patients with Distal Cholangiocarcinoma and Pancreatic Ductal A… Co-author DOI 10.3390/jcm10153247↗
  6. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2020.102858↗
  7. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. Co-author DOI 10.1016/j.ejso.2020.02.037↗
  8. Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.12.001↗
  9. Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study. Co-author DOI 10.1186/s12885-020-6690-1↗
  10. Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma? Co-author DOI 10.1186/s12893-020-00835-3↗
  11. Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1186/s12957-019-1637-1↗
  12. Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. Co-author DOI 10.1016/j.suronc.2018.07.014↗
  13. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  14. Prognostic Value of Molecular Subtypes in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000787↗
  15. A 25-gene classifier predicts overall survival in resectable pancreatic cancer. Co-author DOI 10.1186/s12916-017-0936-z↗
  16. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individua… Co-author DOI 10.15252/emmm.201606975↗
  17. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. Co-author DOI 10.18632/oncotarget.10776↗
  18. Prognostic value of PDL1 expression in pancreatic cancer. Co-author DOI 10.18632/oncotarget.11685↗
  19. Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study. Co-author DOI 10.18632/oncotarget.9861↗
  20. Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ajpath.2014.11.029↗
  21. A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Co-author DOI 10.18632/oncotarget.2685↗
  22. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.3510↗
  23. Pancreatic Adenocarcinoma with Early Intense Enhancement in Harmonic Contrast-Endoscopic Ultrasound and High Strain Ratio in Elastometry (with video). Co-author DOI 10.4103/2303-9027.117722↗

Trials 1

  1. Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia Principal investigator NCT04753229↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Olivıer Turrini · 17 shared papers, 2015–2026 · strength 1.79
  2. Jonathan Garnier · 11 shared papers, 2016–2026 · strength 1.70
  3. Marine Gilabert · 17 shared papers, 2015–2020 · strength 1.20
  4. Jean‐Robert Delpéro · 12 shared papers, 2016–2021 · strength 1.02
  5. Marc F. Giovannini · 13 shared papers, 2013–2023 · strength 0.95
  6. Anaïs Palen · 3 shared papers, 2021–2026 · strength 0.81
  7. Nelson Dusetti · 9 shared papers, 2015–2026 · strength 0.74
  8. Ugo Marchèse · 6 shared papers, 2019–2021 · strength 0.67
  9. Juan Iovanna · 9 shared papers, 2015–2023 · strength 0.53
  10. Jean‐Luc Raoul · 9 shared papers, 2015–2018 · strength 0.50
  11. Nicolas Alejandro Fraunhoffer · 2 shared papers, 2023–2026 · strength 0.41
  12. Brice Chanez · 2 shared papers, 2023–2026 · strength 0.41
  13. Laurence Moureau-Zabotto · 4 shared papers, 2018–2020 · strength 0.40
  14. Julie Roques · 3 shared papers, 2017–2026 · strength 0.39
  15. Pauline Duconseil · 7 shared papers, 2015–2020 · strength 0.37
  16. Odile Gayet · 7 shared papers, 2015–2020 · strength 0.33
  17. Rémy Nicolle · 4 shared papers, 2017–2023 · strength 0.31
  18. Clémentine Gaucher · 1 shared paper, 2026 · strength 0.27
  19. Céline Loncle · 6 shared papers, 2015–2017 · strength 0.25
  20. Mehdi Ouaïssi · 6 shared papers, 2015–2017 · strength 0.25
  21. Véronique Secq · 5 shared papers, 2015–2017 · strength 0.21
  22. Daniel Birnbaum · 3 shared papers, 2016–2017 · strength 0.19
  23. François Bertucci · 3 shared papers, 2016–2017 · strength 0.19
  24. Émilie Mamessier · 3 shared papers, 2016–2017 · strength 0.19
  25. David Jérémie Birnbaum · 3 shared papers, 2016–2017 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.